The letter from Dr Ronald S Go 1 raised interesting questions that will be important to resolve in future studies of chronic myelogenous leukemia (CML).
Dr Go stated that there was a published case of CML with the JAK2 V617F mutation earlier to our report; 2,3 however, that was a case of CML having an atypical clinical course, with a late appearance of the Philadelphia chromosome. [4] [5] [6] In our report, we described a typical CML case with an onset before the development of erythrocytosis.
7
The reports by us 7 and Hussein et al. 8 describing two typical CML cases, could not prove that the Ph þ clone and the JAK2 mutation clone were identical. The results of sequential analyses quantifying the JAK2 V617F mutation and the BCR/ABL fusion gene led us to speculate that these were nonidentical clones. 7, 8 Recently, Scott et al.
9 reported on polycythemia vera patients who were negative for the JAK2 V617F mutation, but had other mutations in exon 12 of the JAK2 gene, including deletions (F537-K539delinsL and N542-E543del) and point mutations (H538QK539L and K539L). Results of previous studies have led to speculation that there is no correlation with the JAK2 V617F mutation and transformation from the chronic phase of CML to the accelerated phase (AP) and blastic crisis (BC), 10 but there are no studies for other mutations of the JAK2 gene. Many CML patients resistant to imatinib may possess gene mutations in the A-and P-loop, or gene amplification of the BCR/ABL fusion gene. As MAPK and JAK-STAT pathways are very important for disease initiation and progression, acquired JAK2 gene mutations may be another cause of imatinib resistance as a late event. For example, there has been a report of a BCR/JAK2 fusion gene in imatinib-resistant CML.
11 Thus, evaluation of JAK2 gene status in CML patients transformed to the AP or BC, and in patients who have acquired imatinib resistance, is necessary, and we are now investigating it. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif Leukemia (2007 Leukemia ( ) 21, 2052 Leukemia ( -2054 doi:10.1038/sj.leu.2404839; published online 19 July 2007 In acute myeloid leukaemia (AML), NPM1 gene mutations occur almost exclusively at exon 12. 1 Therefore, we read with great interest the recent letter by Pitiot et al.
2 on a novel type of mutation occurring at exon 11 of the NPM1 gene, which generates a 274-amino-acid NPM leukaemic mutant truncated at its C-terminal end. This mutation is very similar to the one we previously described.
3 Specifically, we first identified a truncated form of NPM protein generated by a mutation at NPM1 exon 11, which localizes aberrantly in the cytoplasm of leukaemic cells due to the concerted action of two abnormalities: loss of tryptophan residues 288 and 290 (which impairs the mutated NPM protein capability to bind nucleoli) and the new Rev-type NES motif (VFLI) at the mutant C terminus. 3 We concluded that a common molecular theme 4 underlies the exaggerated nuclear export and cytoplasmic accumulation of 
